QQ客服 官方微博 反馈留言

浏览/检索结果: 共4条，第1-4条 帮助 已选(0)清除 条数/页：5101520253035404550556065707580859095100   排序方式：请选择发表日期升序发表日期降序作者升序作者降序提交时间升序提交时间降序题名升序题名降序 Choosing Optimal Antifungal Agents To Prevent Fungal Infections in Nonneutropenic Critically Ill Patients: Trial Sequential Analysis, Network Meta-analysis, and Pharmacoeconomic Analysis 期刊论文 ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2017, 卷号: 61 作者:  Wang, Yan;  Xie, Jiao;  Xing, Yuanming;  Chen, Lu;  Li, Ying 收藏  |  浏览/下载：19/0  |  提交时间：2019/11/26 invasive fungal infection  network meta-analysis  critically ill patients  untargeted treatment  pharmacoeconomic analysis   Memantine for treatment of moderate or severe Alzheimer's disease patients in urban China: clinical and economic outcomes from a health economic model 期刊论文 EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2015, 卷号: 15, 期号: 4 作者:  Hu, Shanlian;  Yu, Xin;  Chen, Shengdi;  Clay, Emilie;  Toumi, Mondher 收藏  |  浏览/下载：3/0  |  提交时间：2019/12/13 aggression  Alzheimer's disease  cost-saving  disease burden  memantine  pharmacoeconomic   Guidance Document: Global Pharmacoeconomic Model Adaption Strategies. 期刊论文 Value in health regional issues, 2014, 卷号: 5 作者:  Daniel Mullins C;  Onwudiwe Nneka C;  Branco de Araújo Gabriela Tannus;  Chen Wen;  Xuan Jianwei 收藏  |  浏览/下载：3/0  |  提交时间：2019/12/19 cost-effectiveness analysis  health technology assessment  pharmacoeconomic model   Guanxin II (II) for the management of coronary heart disease. 期刊论文 Chinese Journal of Integrative Medicine, 2009, 卷号: 15, 期号: 6, 页码: 472-476 作者:  Feng Qin 秦 锋;  Xi Huang 黄 熙 收藏  |  浏览/下载：2/0  |  提交时间：2019/12/03 Guanxin II  coronary heart disease  quality control  pharmacokinetics  pharmacology  adverse event  pharmacoeconomic assessment